Mid Diagnosed 2026-10-25 13:29:41 KST
A
AVBP AI Stock Diagnostic Report
ArriVent reports phase 1 data for cancer drug ARR-217 ArriVent announced Phase 1 data for the anticancer drug ARR-217, but as the direction of the results is not clear, the stock price impact is judged to be neutral.
View Source Article ↗ AI CATALYST SCORE 50 / 100 Score computed by Sentinel V12
REFERENCE PRICE Not measured Reference entry price at analysis time
AI REFERENCE SCORE A reference score computed by the analysis engine from news and filings.
Report Info
Tier Mid
Diagnosed At 2026-10-25 13:29:41
Content Review Reviewed
Company Facts
Next Ex-Dividend Date Collecting
Next Earnings Date Collecting
Latest SEC Filing 2026-10-19T08:08:31-04:00 Data Composition Shows Sentinel V12's AI analysis, plus (for S-Class) Python Engine technical indicators and stored OHLC data.
+ ANALYSIS HISTORY
AVBP Analysis History (Last 30 Days)